{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ed-Driouch C"],"funding":["Bourse Région Pays de la Loire","Agence Nationale de la Recherche","Research and Innovation Programme"],"pagination":["1863-1873"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9735373"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(12)"],"pubmed_abstract":["<h4>Objective</h4>Multiple sclerosis (MS) is a multifactorial disease with increasingly complicated management. Our objective is to use on-demand computational power to address the challenges of dynamically managing MS.<h4>Methods</h4>A phase 3 clinical trial data (NCT00906399) were used to contextualize the medication efficacy of peg-interferon beta-1a vs placebo on patients with relapsing-remitting MS (RRMS). Using a set of reference patients (PORs), selected based on adequate features similar to those of an individual patient, we visualize disease activity by measuring the percentage of relapses, accumulation of new T2 lesions on MRI, and worsening EDSS during the clinical trial.<h4>Results</h4>We developed MS Vista, a functional prototype of clinical decision support system (CDSS), wit"],"journal":["Annals of clinical and translational neurology"],"pubmed_title":["Multiple sclerosis clinical decision support system based on projection to reference datasets."],"pmcid":["PMC9735373"],"funding_grant_id":["754995","2019_11235","ANR‐17‐RHUS‐0010","ANR‐21‐RHUS‐0014","ANR-21-RHUS-0014","ANR-17-RHUS-0010"],"pubmed_authors":["Le Page E","Kerbrat A","Combes B","Vince N","Mars F","Dumas C","Ed-Driouch C","Pasquier G","Limou S","Gourraud PA","Simon F","Cheneau F","Laplaud DA","Edan G"],"additional_accession":[]},"is_claimable":false,"name":"Multiple sclerosis clinical decision support system based on projection to reference datasets.","description":"<h4>Objective</h4>Multiple sclerosis (MS) is a multifactorial disease with increasingly complicated management. Our objective is to use on-demand computational power to address the challenges of dynamically managing MS.<h4>Methods</h4>A phase 3 clinical trial data (NCT00906399) were used to contextualize the medication efficacy of peg-interferon beta-1a vs placebo on patients with relapsing-remitting MS (RRMS). Using a set of reference patients (PORs), selected based on adequate features similar to those of an individual patient, we visualize disease activity by measuring the percentage of relapses, accumulation of new T2 lesions on MRI, and worsening EDSS during the clinical trial.<h4>Results</h4>We developed MS Vista, a functional prototype of clinical decision support system (CDSS), wit","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-27T18:53:06.818Z","creation":"2025-04-19T09:53:08.064Z"},"accession":"S-EPMC9735373","cross_references":{"pubmed":["36412095"],"doi":["10.1002/acn3.51649"]}}